Smoothened inhibitors in the treatment of advanced basal cell carcinomasKunstfeld, RainerCurrent Opinion in Oncology: March 2014 - Volume 26 - Issue 2 - p 184–195 doi: 10.1097/CCO.0000000000000058 MELANOMA AND OTHER SKIN NEOPLASMS: Edited by Reinhard Dummer Abstract Author Information Purpose of review The Hedgehog pathway has been identified as a key element in the development of many forms of cancer. Smoothened (Smo) inhibitors are known to beneficially interfere with the Hedgehog pathway and are currently under investigation as anticancer drugs for many tumor entities. Reviewed here are the most recent developments in clinical research on Smo inhibitors for the treatment of advanced basal cell carcinoma (BCC). Recent findings When reviewing the literature of the past 12 months, it is striking to see the rapid evolution of the field. Compounds that have been presented as powerful new drug candidates 12 months ago have now been discontinued, whereas new ones have emerged. Reports on 13 drug candidates have been identified: one marketed, vismodegib, eight currently under development (phase I–II) and four for which clinical investigation for BCC is currently not being pursued. Summary Smo inhibitors are a promising drug class for the treatment of BCC. To date, most candidates are in early stage development and are expected to enter the market in approximately 5–8 years, if successful. Division of General Dermatology, Department of Dermatology, Medical University of Vienna, Vienna, Austria Correspondence to University Professor Dr Rainer Kunstfeld, Division of General Dermatology, Department of Dermatology, Medical University of Vienna, Währinger Gürtel 18-20, A-1090 Vienna, Austria. Tel: +43 1 40400 6262; fax: +43 1 40400 7699; e-mail: email@example.com © 2014 Lippincott Williams & Wilkins, Inc.